Walgreens Boots Alliance Reports Q3 Beat, Guidance Maintained

Walgreens Boots Alliance, Inc.(NASDAQ:WBA) reported its Q3 results, with EPS of $0.96 coming in better than the Street estimate of $0.91. Revenue was $32.6 billion, above the Street estimate of $32.01 billion.
The beat was driven by better than forecasted Covid vaccines and tests, a sharp rebound in the International segment, offset by higher than expected losses in the burgeoning Walgreens Health segment.
The company maintained its full 2022-year guidance. However, analyst at Deutsche Bank model core US pharmacy EBITDA ex vaccines to be down 26.5% year-over-year, and the company’s guidance commentary suggests the US EBITDA could be down approximately 25% in Q4, implying a weakened core as the run rate headed into 2023.

Follow us on Google news for more updates and News

Full Disclaimer



Get the most important news and analyses for Free.

Thank you for subscribing.

Something went wrong.